Plasmacytoid dendritic cell leukemia with potent antigen-presenting ability.

Abstract

We report 2 patients with plasmacytoid dendritic cell leukemia (pDCL) expressing CD4, CD56, CD33, CD36, HLA-DR, CD123, CD86 and CD83 in the absence of lineage markers (myeloid, B, T or natural killer cells) except for CD33. Culturing leukemic blasts of both cases with IL-3 for 4 days increased the expression of surface molecules associated with antigen presentation, e.g. CD1a and CD40. Leukemic blasts of both cases possessed a considerable level of antigen-presenting ability to allogeneic lymphocytes in mixed leukocyte cultures. Culturing the blasts with IL-3 for 4 days markedly increased allogeneic antigen presenting ability. Combined with data showing evident graft-versus-leukemia effects without graft-versus-host disease in a cord blood stem cell transplanted pDCL case, leukemic cells in pDCL may act as potent antigen presenting cells in vivo, too.

• Authors: Miwako Narita, Takashi Kuroha, Norihiro Watanabe, Shigeo Hashimoto, Junjiro Tsuchiyama, Nozomi Tochiki, Anri Saitoh, Noriyuki Satoh, Tatsuo Furukawa, Ken Toba, Ichiro Fuse, Yoshifusa Aizawa, Masuhiro Takahashi
• Journal: Acta haematologica (Acta Haematol) Vol. 120 Issue 2 Pg. 91-9 ( 2008) ISSN: 1421-9662 [Electronic] Switzerland
• PMID: 18948686 (Publication Type: Case Reports, Journal Article)

Chemical References

• Interleukin-3

Topics

• Aged
• Antigen Presentation
• Cell Lineage
• Cord Blood Stem Cell Transplantation
• Dendritic Cells (immunology, pathology)
• Graft vs Leukemia Effect
• Humans
• Immunophenotyping
• Interleukin-3 (pharmacology)
• Leukemia (immunology, pathology, therapy)
• Male